| ¿µ¹® | purpura | ÇÑ±Û | ÀÚ»ö¹ÝÁõ |
|---|---|---|---|
| ¼³¸í | ÇǺγ»ÀÇ ÃâÇ÷·Î ÀÎÇÏ¿©, ÇǺΠǥÇǸ¦ ÅëÇÏ¿© ½±°Ô º¸ÀÌ´Â ÀÚÈ«»ö ȤÀº Àû°¥»ö ¹ÝÁ¡À» Ư¡À¸·Î ÇÏ´Â ÀÏ·ÃÀÇ ÁúȯÀ» ÃÑĪÇÏ´Â ¿ë¾îÀÌ´Ù. ´ë°³ È«¹Ý°ú ±¸º°ÇØ¾ß ÇÏ´Â µ¥ È«¹ÝÀº ÇǺιØÀÇ Ç÷°üÀÌ ÆØÃ¢ÇÏ¿© ºÓ°Ô º¸ÀÌ´Â Çö»óÀ¸·Î Åõ¸íÇÑ ÀÚ¸¦ ÀÌ¿ëÇÏ¿© ÇǺθ¦ ´·¯¼ °üÂûÇØº¸¸é ½±°Ô ±¸º°ÀÌ °¡´ÉÇÏ´Ù. À̶§ È«¹ÝÀº ºÓÀº »öÀÌ ¾ø¾îÁöÁö¸¸, ÀÚ¹ÝÀº ºÓÀº »öÀÌ ¾ø¾îÁöÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | corticosteroid | ÇÑ±Û | ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å |
|---|---|---|---|
| ¼³¸í | ÄáÆÏÀ§¿¡ ÀÖ´Â »ï°¢»ÔÀÇ ÇüŸ¦ Áö´Ñ ±â°üÀÎ ºÎ½ÅÀÇ °ÑºÎºÐÀÎ °ÑÁú¿¡¼ ¸¸µé¾îÁö´Â ¹°Áú·Î È£¸£¸óÀÇ ÀÏÁ¾. ÄÚ¸£Æ¼°í½ºÅ×·ÎÀ̵å´Â ±× ¿ªÇÒ¿¡ µû¶ó¼ ´ÙÀ½°ú °°Àº 3°¡Áö·Î ³ª´©¾îÁø´Ù. 1.±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å(glucocorticoid)-Áö¹æÁú, ´çÁú, ´Ü¹éÁúÀÇ ´ë»ç¿¡ °ü°èÇϴ ȣ¸£¸ó. Áö¹æÁú°ú ´Ü¹éÁúÀ» ºÐÇØÇØ¼ ´çÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÏ°í ¶Ç Ã¼³»¿¡ ÀúÀåµÇ¾î ÀÖ´Â ´çÁúÀ» Ç÷¾×¼ÓÀ¸·Î ¹èÃâÇÏ´Â ¿ªÇÒÀ» Çϴ ȣ¸£¸ó. ºÎ½Å°ÑÁú¿¡¼ ¸¸µé¾îÁö´Â ´ç·ùÄÚ¸£Æ¼ÄÚÀ̵å´Â ´ëºÎºÐ ÄÚ¸£Æ¼¼Ö(cortisol)À̶ó´Â ¹°ÁúÀÌ´Ù. 2.±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵å(mineralocorticoid)-ü³»ÀÇ ÀüÇØÁú°ú ¼öºÐÀÇ Á¶Àý¿¡ °ü¿©Çϴ ȣ¸£¸ó. ÄáÆÏ¿¡ ÀÛ¿ëÇÏ¿© ¼öºÐ°ú ³ªÆ®·ýÀÇ ¹è¼³À» ¾ïÁ¦ÇÏ¿© ¼öºÐ, ³ªÆ®·ýÀÇ Ã¼³» ¾çÀ» Áõ°¡½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù. 3.¿¡½ºÆ®·Î°Õ, ¾Èµå·Î°Õ-¼ºÈ£¸£¸óÀ¸·Î ¼ºÀÇ ºÐȳª ¿©·¯ °¡Áö »ý½Ä¿¡ °ü·ÃµÈ ¿ªÇÒÀ» ÇÑ´Ù. ¾Ë¾ÆµÎ¾î¾ß ÇÒ °ÍÀº ºÎ½Å°ÑÁú¿¡¼ »ý»êµÈ À§ÀÇ 3°¡Áö È£¸£¸óÀº Á¤È®È÷ ±â´ÉÀÇ ±¸ºÐÀÌ ÀÖ´Â °ÍÀÌ ¾Æ´Ï°í ´Ù¸¥ È£¸£¸óÀÇ ÀÛ¿ëµµ °¡Áö°í ÀÖ´Â ¼ö°¡ ¸¹´Ù. Áï ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵嵵 ¾à°£ÀÇ ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ¿ªÇÒÀÌ ÀÖ°í, ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵嵵 ¾à°£ÀÇ ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ¿ªÇÒÀÌ ÀÖ´Ù. |
||
| ITP | idiopathic thrombocytopenic purpura; immune thrombocytopenia; immunogenic thrombocytopenic purpura; ... |
|---|---|
| CMO | Corticosteroid Methyl-Oxidase |
| 17-OHCS | 17-OH(Hydroxy)-Corticosteroid |
| CBG | capillary blood gases; coronary bypass graft; corticosteroid-binding globulin; cortisol-binding glob... |
| CBGv | corticosteroid-binding globulin variant |
| 11-OHCS | 11-hydroxy-corticosteroid |
|---|---|
| 17-OHCS | 17-hydroxy-corticosteroid |
| C | Corticosteroid |
| CBG | Corticosteroid Binding Globulin |
| CR | Corticosteroid-resistant |
| corticosteroid | <drug, endocrinology, pharmacology> Any of the steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to the release of adrenocorticotrophin or adrenocorticotropic hormone (ACTH) by the pituitary gland, to any of the synthetic equivalents of these steroids or to angiotensin II. They are divided, according to their predominant biological activity, into three major groups: glucocorticoids (e.g. Cortisol, cortisone), chiefly influencing carbohydrate, fat and protein metabolism, mineralocorticoids (for example aldosterone), affecting the regulation of electrolyte and water balance and C19 androgens. Some corticosteroids exhibit both types of activity in varying degrees and others exert only one type of effect. The corticosteroids are used clinically for hormonal replacement therapy, for suppression of ACTH secretion by the anterior pituitary, as antineoplastic, antiallergic and anti-inflammatory agents and to suppress the immune response. Synonym: adrenocortical hormone, corticoid. (13 Nov 1997) |
|---|---|
| corticosteroid-binding globulin | <chemical> Chemical name: Transcortins (12 Dec 1998) |
| corticosteroid-binding protein | <chemical> Chemical name: Transcortins (12 Dec 1998) |
| corticosteroid cream | <drug, pharmacology> This is a large group of trade name medications that contain an anti-inflammatory steroid. These cream based medications all contain either hydrocortisone in varying concentrations or a synthetic steroid with much greater potency. This type of medications is useful in the treatment of a large number of inflammatory rashes. Caution: higher potency creams can cause side effects. Examples include hydrocortisone, dexamethasone, flunisolide, fluocinonide, fluprednisolone, Aclovate, Alphatrex, Aristocort, Betatrex, Cortone, Diprolene, Valisone, Halog, Hytone, Kenalog, Lidex, Lotrisone, Synalar, Synemol, Topicort, Vytone, Westcort and Vioform. (27 Sep 1997) |
| corticosteroid-induced acne | The exacerbation of acne after corticosteroid use is a common drug reaction seen in adolescents. Lessening the dose of the corticosteroid will often diminish this effect. (27 Sep 1997) |
| corticosteroid-induced glaucoma | <ophthalmology> Glaucoma caused by a hereditary predisposition in which local instillation of eyedrops containing corticosteroid causes increased intraocular pressure. (05 Mar 2000) |
| corticosteroid-induced striae | <dermatology> High-dose glucocorticoid therapy causes atrophy of the skin and a failure of the normal regenerative process. Purple striae often develop over the individual's trunk or thighs. The colour fades when the drug is stopped, but the dermal atrophy remains. (27 Sep 1997) |
| corticosteroid side-chain-isomerase | <enzyme> Converts 11-deoxycorticosterone to 20-hydroxy-3-oxypregn-4-en-21-al; also acts as an epimerase at c-20 Registry number: EC 5.3.1.21 Synonym: corticosteroid side chain isomerase, ccsci (26 Jun 1999) |
| acute vascular purpura | <dermatology> This relatively rare disorder is characterised by skin purpura, joint pains, abdominal pain and renal disease (glomerulonephritis). Although Henoch-Schonlein purpura or anaphylactoid purpura, is thought to be a immune complex mediated disease, its exact cause is unknown. Its typical benign coarse can, however, include renal failure. (27 Sep 1997) |
| allergic purpura | Nonthrombocytopenic purpura due to sensitization to foods, drugs, and insect bites. Synonym: anaphylactoid purpura. (05 Mar 2000) |
| anaphylactoid purpura | <dermatology> This relatively rare disorder is characterised by skin purpura, joint pains, abdominal pain and renal disease (glomerulonephritis). Although Henoch-Schonlein purpura or anaphylactoid purpura, is thought to be a immune complex mediated disease, its exact cause is unknown. Its typical benign coarse can, however, include renal failure. (27 Sep 1997) |
| autoimmune thrombocytopenia purpura | <haematology> A rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding. The platelet count becomes exceedingly low and spontaneous bleeding from the gums, gastrointestinal tract and nose can be seen. Physical examination may demonstrate enlargement of the spleen. A typical rash occurs to do microscopic haemorrhage of small blood vessels in the skin. Platelet counts under 10,000 can lead to spontaneous haemorrhage into the brain causing death. Treatment with corticosteroids is generally effective. Surgical removal of the spleen (splenectomy) is reserved for some patients. Anti-platelet antibodies are detectable in some cases. It may present in either an acute or a chronic form. Acronym: ITP (20 Sep 2002) |
| Waldenstrom's purpura | <haematology> A condition characterised by proliferation of cells resembling lymphocytes or plasma cells in the bone marrow, anaemia, increased sedimentation rate and hyperglobulinaemia. Physical findings include mucosal bleeding, skin purpura and enlargement of the lymph nodes, liver and spleen. (27 Sep 1997) |
| Henoch-Schonlein purpura | <dermatology> This relatively rare disorder is characterised by skin purpura, joint pains, abdominal pain and renal disease (glomerulonephritis). Although Henoch-Schonlein purpura or anaphylactoid purpura, is thought to be a immune complex mediated disease, its exact cause is unknown. Its typical benign coarse can, however, include renal failure. (27 Sep 1997) |
| Henoch's purpura | <dermatology> This relatively rare disorder is characterised by skin purpura, joint pains, abdominal pain and renal disease (glomerulonephritis). Although Henoch-Schonlein purpura or anaphylactoid purpura, is thought to be a immune complex mediated disease, its exact cause is unknown. Its typical benign coarse can, however, include renal failure. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|